Immunology Biosimilars Market Research 2024-2030, Profiles of Key Players - F. Hoffmann-La Roche, Merck, Eli Lily,. Pfizer, Novartis, Teva, Boehringer Ingelheim, Celltrion, Samsungbioepis, Amgen
November 14, 2024 07:14 ET
|
Research and Markets
Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel,...
Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review 2024: Drug Code/INN, Patent/Expiry, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 09:59 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides...
Adalimumab (Humira) Biosimilars Pipeline Review 2024: A Recombinant Human IgG1 mAb - Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 09:57 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Adalimumab (Humira) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on...
Ranibizumab (Lucentis) Biosimilars Pipeline Review: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 09:54 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Ranibizumab (Lucentis) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information...
Ustekinumab (Stelara) Biosimilars Pipeline Review: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 09:53 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Ustekinumab (Stelara) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides basic...
US Biosimilar Market Research 2024-2028 Featuring Leading Players - Pfizer, Novartis, Amgen, Samsung Biologics, Celltrion, and Viatris
August 12, 2024 05:28 ET
|
Research and Markets
Dublin, Aug. 12, 2024 (GLOBE NEWSWIRE) -- The "US Biosimilar Market: Insights & Forecast (2024-2028)" report has been added to ResearchAndMarkets.com's offering.The US biosimilar market is...
Biosimilars Training Course (2-Days Online: October 1-2, 2024) - Global Considerations and Strategies for Biotech/Biosimilar Products and Regulatory Pathways in EU and US
July 03, 2024 11:25 ET
|
Research and Markets
Dublin, July 03, 2024 (GLOBE NEWSWIRE) -- The "Biosimilars Training Course" conference has been added to ResearchAndMarkets.com's offering. Prepare for the biosimilar market growth as some of the...
Biosimilars Training Course: Prepare for Growth as Some of the World's Best-known Biologics Face Patent Expiration in the Coming Years (ONLINE EVENT)
June 20, 2024 04:55 ET
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "Biosimilars Training Course" conference has been added to ResearchAndMarkets.com's offering. Prepare for the biosimilar market growth as some of the...
Global Biosimilar Contract Manufacturing Market Forecast 2024-2034 | A Projected $48.67 Billion Opportunity with Profiles of 10+ Leading Market Players | Oncology Applications in North America Dominate
June 05, 2024 03:36 ET
|
Research and Markets
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Global Biosimilar Contract Manufacturing Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The...
Global Biobetters Market Analysis to 2034 by Drug Class, Disease Indication, Route of Administration, Distribution Channel, and Region, Featuring Exhaustive Profiles of the Top 10+ Players
April 09, 2024 11:54 ET
|
Research and Markets
Dublin, April 09, 2024 (GLOBE NEWSWIRE) -- The "Global Biobetters Market by Drug Class, by Disease Indication, by Route of Administration, by Distribution Channel, and By Region" report has been...